AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27785095
Drug: Nattokinase (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nattokinase (100 mg/d)
Trial: 11167594
Drug: Adjuvant systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant systemic therapy (including chemotherapy)
Trial: 11167594
Drug: More than
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More than one course of chemotherapy
Trial: 9728898
Drug: Verapamil (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (240 mg/day for 2 days)
Trial: 1424416
Drug: Fluvoxamine 50
RxNorm normalized name: fluvoxamine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine 50 mg
Trial: 277253
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hyperbaric oxygen and misonidazole
Trial: 30095536
Drug: Opicinumab (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opicinumab (100 mg/kg intravenous every 4 weeks for 6 infusions)
Trial: 21487327
Drug: 7‐valent pneumococcal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7‐valent pneumococcal conjugate vaccine + DTPa‐IPV‐Hib
Trial: 19555810
Drug: Flavocoxid (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavocoxid (500 mg BID)
Trial: 15037526
Drug: Naproxen (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (500 mg BID)
Trial: 9824786
Drug: Rifampicin 300
RxNorm normalized name: Rifampicin 300 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 300 mg/day for 10 days
Trial: 9824786
Drug: Rifabutin 300
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifabutin 300 mg/day for 10 days
Trial: 2509069
Drug: Netilmicin 300
RxNorm normalized name: netilmicin
DrugBank: Netilmicin (DB00955)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Netilmicin 300 mg once daily (group A)
Trial: 2509069
Drug: Netilmicin 100
RxNorm normalized name: netilmicin 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netilmicin 100 mg three times daily (group B)
Trial: 31898756
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (HA) cheek fillers injection
Trial: 28109247
Drug: Internet- and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet- and mobile-based intervention (IMI) for depression prevention, based on cognitive behavioral therapy (CBT) principles, comprising six weekly modules and two booster sessions.
Trial: 9572900
Drug: Colon-Targeted Delivery
RxNorm normalized name: Sus scrofa colon preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colon-Targeted Delivery Capsule
Trial: 7922092
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (prednisolone, cyclosporin A, azathioprine)
Trial: 7922092
Drug: Low-dose cyclosporin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose cyclosporin, azathioprine, and prednisolone
Trial: 7922092
Drug: High-dose cyclosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclosporin and prednisolone
Trial: 7922092
Drug: High-dose cyclosporin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclosporin, nifedipine, and prednisolone
Trial: 3136953
Drug: Heparin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin alone (27 patients)
Trial: 3136953
Drug: Maintenance infusion
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance infusion of rt-PA at 0.8 mg/kg during 4 hours (25 patients)
Trial: 31713266
Drug: 1064-nm Nd:YAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1064-nm Nd:YAG laser treatment
Trial: 30587761
Drug: 250 mg/day
RxNorm normalized name: alpelisib 250 mg/day (200 mg x 1 and 50 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg/day of elemental Mg for three months
Trial: 24356481
Drug: golimumab 100
RxNorm normalized name: golimumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: golimumab 100 mg + placebo
Trial: 23327125
Drug: Midazolam (MDZ)
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam (MDZ) 0.2 mg/kg
Trial: 15941886
Drug: Plant sterols
RxNorm normalized name: Plant Sterols/Stanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterols (1.8 g/d)
Trial: 10622655
Drug: Felodipine infusion
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felodipine infusion during the hypothermic period of cardiopulmonary bypass
Trial: 10622655
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no felodipine infusion)
Trial: 8622115
Drug: Isepamicin (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isepamicin (8 or 15 mg/kg once daily)
Trial: 8622115
Drug: Isepamicin (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isepamicin (7.5 mg/kg twice daily)
Trial: 28933613
Drug: Partnered ballroom
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partnered ballroom dancing, 1 hour, twice a week for 10 weeks, led by professional dance teachers.
Trial: 18270675
Drug: S(+)-ketamine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S(+)-ketamine (0.25 mg/kg BW bolus followed by infusion of 0.06 mg/kg BW/h)
Trial: 18270675
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion (>3 mg/kg BW/h)
Trial: 10549452
Drug: Foaming tablet
RxNorm normalized name: Rectal Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foaming tablet
Trial: 8154255
Drug: Retrobulbar anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrobulbar anesthesia with 150 I.U. hyaluronidase (Kinetin) added to 4 mg lidocaine 2% with adrenalin
Trial: 24882370
Drug: Spa treatment
RxNorm normalized name: Salicylic Acid 5 mg in 1 mL TOPICAL LOTION [ageLOC LumiSpa Treatment Cleanser Acne]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spa treatment combined with consultation with dietician
Trial: 19535425
Drug: Iron (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron (25 mg) and folic acid (100 microg) for 90 days
Trial: 19535425
Drug: Iron (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron (25 mg) and folic acid (100 microg) with multivitamins and/or anthelminthics
Trial: 19535425
Drug: Iron (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron (25 mg) and folic acid (100 microg) with adherence higher than the median
Trial: 19535425
Drug: High-dose daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose daily iron+folic acid
Trial: 17595891
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg rivaroxaban once, twice or three times daily, or 10, 20 or 30 mg rivaroxaban twice daily
Trial: 9709470
Drug: Chlorambucil (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorambucil (0.15 mg/kg/day for months 2, 4, and 6) and steroids (1 g methyl‐prednisolone i.v. on three consecutive days, followed by oral prednisone 0.5 mg/kg/day for months 1, 3, and 5)
Trial: 9709470
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide (1.5‐2.0 mg/kg/day for 1 year) and steroids in a comparable dose
Trial: 1870651
Drug: Compulsory inpatient
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compulsory inpatient treatment
Trial: 1870651
Drug: Choice of
RxNorm normalized name: HYDROGEN PEROXIDE 30 mg in 1 mL TOPICAL LIQUID [MediChoice of Hydrogen Peroxide 3 10 Volume]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choice of treatment options
Trial: 6314140
Drug: Epinephrine infusion
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine infusion at 0.1 microgram per kilogram per minute
Trial: 6314140
Drug: Isoproterenol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol infusion at 0.02 micrograms per kilogram per minute
Trial: 6314140
Drug: Epinephrine infusion
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine infusion at 0.05 micrograms per kilogram per minute after administration of ICI 118551 (2.5 or 5 mg)
Trial: 6314140
Drug: Epinephrine infusion
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine infusion after placebo
Trial: 27726259
Drug: Programmed sports
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programmed sports therapy (PST) for 6 months
Trial: 25231896
Drug: Mirogabalin 5
RxNorm normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Mirogabalin 5 mg/day
Trial: 25231896
Drug: Mirogabalin 10
RxNorm normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Mirogabalin 10 mg/day
Trial: 28371941
Drug: Mirogabalin 15
RxNorm normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Mirogabalin 15 mg/day
Trial: 28371941
Drug: Mirogabalin 20
RxNorm normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Mirogabalin 20 mg/day
Trial: 28371941
Drug: Mirogabalin 30
RxNorm normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Mirogabalin 30 mg/day
Trial: 21769661
Drug: Combined vertebroplasty
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined vertebroplasty with antiresorptive agent
Trial: 9795914
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg lamivudine once daily
Trial: 29428872
Drug: Ramipril treatment
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramipril treatment
Trial: 19206035
Drug: Four-week inpatient
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-week inpatient treatment
Trial: 12207834
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g cis‐9,trans‐11-trans‐10,cis‐12 isomeric blend (50 : 50) CLA
Trial: 12207834
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g cis‐9,trans‐11-trans‐10,cis‐12 isomeric blend (80 : 20) CLA
Trial: 31932108
Drug: Pazopanib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 600 mg once daily and fosbretabulin 54 mg/m2 on days 1, 8, and 15 (phase 1b)
Trial: 31932108
Drug: Pazopanib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 600 mg once daily and fosbretabulin 54 mg/m2 (experimental arm)
Trial: 31932108
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg once daily (control arm)
Trial: 28285280
Drug: Delayed cord
RxNorm normalized name: Bos taurus umbilical cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed cord clamping (60 s) with ergometrine (500 µg)
Trial: 28010726
Drug: Anti-TNF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF treatment
Trial: 24307311
Drug: Chaiqin Chengqi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chaiqin Chengqi Decoction (CQCQD) administered by gastric perfusion (50 mL/2 h) and retention enema (200 mL/6 h) for 7 days
Trial: 21876349
Drug: Bindarit (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bindarit (1,200 mg/day)
Trial: 19236643
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg x kg(‐1) propofol
Trial: 19236643
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg x kg(‐1) propofol
Trial: 11129620
Drug: Midazolam-fentanyl (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam-fentanyl (group M) - intravenous midazolam 0.1 mg.kg‐1.h‐1 and fentanyl 25 micrograms.kg‐1 until sternotomy
Trial: 11129620
Drug: Propofol-fentanyl (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol-fentanyl (group P) - intravenous propofol 4 mg.kg‐1.h‐1 and fentanyl 25 micrograms.kg‐1 until sternotomy
Trial: 9085210
Drug: Hexoprenaline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexoprenaline (10 micrograms administered intravenously)
Trial: 8239010
Drug: 0.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/kg diazepam
Trial: 8239010
Drug: 0.03 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03 mg/kg oral atropine
Trial: 3010028
Drug: Atenolol (beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (beta 1-blocker, 50 mg once per day)
Trial: 3010028
Drug: ICI 118,551
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 118,551 (beta 2-blocker, 20 mg t.i.d.)
Trial: 3010028
Drug: ICI 118,551
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 118,551 (beta 2-blocker)
Trial: 3010028
Drug: Atenolol (beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (beta 1-blocker)
Trial: 28077539
Drug: Group R
RxNorm normalized name: Typhus group rickettsia Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group R (remifentanil 0.30 µg kg‐1 min‐1)
Trial: 28077539
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (remifentanil 0.30 µg kg‐1 min‐1 and pre‐anaesthesia butorphanol 20 µg kg‐1)
Trial: 28077539
Drug: Group BF
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group BF (remifentanil 0.30 µg kg‐1 min‐1 and pre‐anaesthesia butorphanol 10 µg kg‐1 combined with flurbiprofen axetil 0.5 mg kg‐1)
Trial: 28077539
Drug: Group S
RxNorm normalized name: Blood group substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group S (sufentanil 0.30 µg kg‐1)
Trial: 11823755
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg olanzapine with 500 mg probenecid
Trial: 11823755
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg risperidone with 500 mg probenecid
Trial: 11823755
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg olanzapine alone
Trial: 11823755
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg risperidone alone
Trial: 10027031
Drug: Propofol infusion,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol infusion, 30 mg.kg‐1.h‐1 (Group P; n = 12)
Trial: 10027031
Drug: Ketamine bolus,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine bolus, 0.5 mg i.v. followed by propofol infusion, 30 mg.kg‐1.h‐1 (Group PK0.5; n = 12)
Trial: 10027031
Drug: Ketamine bolus,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine bolus, 0.75 mg i.v. followed by propofol infusion, 30 mg.kg‐1.h‐1 (Group PK0.75; n = 12)
Trial: 10027031
Drug: Ketamine bolus,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine bolus, 0.25 mg i.v. followed by propofol infusion, 30 mg.kg‐1.h‐1 (Group PK0.25; n = 12)
Trial: 7717488
Drug: Ketamine 2
RxNorm normalized name: esketamine 28 mg nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 2 mg.kg-1
Trial: 7717488
Drug: Ketamine/midazolam 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine/midazolam 2 mg.kg-1 after midazolam pretreatment
Trial: 7717488
Drug: Ketamine/esmolol 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine/esmolol 2 mg.kg-1 with esmolol
Trial: 2030491
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized P4 supplementation (200 mg four times daily)
Trial: 24379596
Drug: Perirenal space
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perirenal space blocking (PSB) + specialized medical therapy (SMT)
Trial: 24379596
Drug: No perirenal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No perirenal space blocking (NPSB) + specialized medical therapy (SMT)
Trial: 16931991
Drug: Patient-controlled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled intravenous morphine
Trial: 11893342
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of epoetin (recombinant human erythropoietin)
Trial: 11893342
Drug: Minimal reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal reduction (10%) in epoetin dose
Trial: 9810889
Drug: Elase ointment
RxNorm normalized name: ELASE OINT
DrugBank: Fibrinolysin (DB05254)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elase ointment (proteolytic ointment)
Trial: 9810889
Drug: Placebo (ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (ointment vehicle)
Trial: 9810889
Drug: Complete ointment
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Complete ointment (Elase)
Trial: 2494014
Drug: Intravenous lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lipid emulsion containing medium‐chain triacylglycerols (MCT) and long‐chain triacylglycerols (LCT)
Trial: 836112
Drug: 125 IU
RxNorm normalized name: Calcium/Vitamin D 200 MG-125 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 IU of human chorionic gonadotropin (HCG) intramuscularly daily for 30 days
Trial: 20840349
Drug: Etanercept (ETN)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept (ETN) 50mg twice weekly (BIW)
Trial: 20840349
Drug: Etanercept (ETN)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept (ETN) 50mg weekly (QW)
Trial: 17320026
Drug: Surrogate markers
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surrogate markers for PMO treatments
Trial: 3306292
Drug: Org OD
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org OD 14 (2.5 mg/day for 12 weeks)
Trial: 28803691
Drug: Topical lavender
RxNorm normalized name: LAVENDER
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical lavender oil ointment
Trial: 28803691
Drug: Night wrist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Night wrist orthotic and placebo ointment
Trial: 27243899
Drug: Mobility Program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobility Program (MP) - assisted ambulation up to twice daily with a behavioral strategy to encourage mobility.
Trial: 27243899
Drug: Usual Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual Care (UC) - received twice-daily visits.
Trial: 23472071
Drug: 1% vaginal
RxNorm normalized name: Mycelex 1% Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% vaginal tenofovir gel
Trial: 12809830
Drug: Rifaximin 600
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin 600 mg per day
Trial: 12809830
Drug: Rifaximin 1200
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin 1200 mg per day
Trial: 12809830
Drug: Rifaximin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin (both doses)
Trial: 1346268
Drug: Epanolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epanolol (200 mg daily)
Trial: 7899788
Drug: Ivermectin administration
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin administration
Trial: 25147013
Drug: Balneohydrotherapy (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balneohydrotherapy (18 days of treatment including Kneipp therapy, walking in a mineral water pool, massage, and bathing in a mineral water tub)
Trial: 8925544
Drug: Heparan sulphate
RxNorm normalized name: Heparan sulphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparan sulphate (100 mg/day for 3-4 months)
Trial: 6418441
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (2 mg 4-times daily)
Trial: 26363305
Drug: Six sessions
RxNorm normalized name: Alternanthera sessilis extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six sessions of cognitive therapy
Trial: 17516769
Drug: Motivational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational therapy
Trial: 20304772
Drug: Airway clearance
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Airway clearance therapy (ACT)
Trial: 10727589
Drug: Prednisone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (1 or 2 mg/kg body weight)
Trial: 9403265
Drug: Povidone-iodine sugar
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone-iodine sugar ointment (P-1, P-2, P-3)
Trial: 9403265
Drug: Povidone-iodine sugar
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone-iodine sugar ointment (P-3)